Judge Approves Consent Decree Against Shamrock Medical Solutions Group - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Judge Approves Consent Decree Against Shamrock Medical Solutions Group


More in GMPs/Validation

A federal judge has approved a consent decree of permanent injunction against Shamrock Medical Solutions Group, Lewis Center, Ohio, and four of its corporate officers and employees for continued drug manufacturing and labeling violations that resulted in the distribution of mislabeled drugs, the FDA reported in a press statement on Sept. 18.

Shamrock Medical repackaged and distributed solid and liquid oral non-sterile drug products for human use to hospitals throughout the United States. FDA reported that inspections found several violations at the facility, including failure by the quality control unit to fully follow its own quality control procedures and to examine packaged and labeled products to ensure correct labeling. The FDA previously had sent warning letters to Shamrock Medical for violating cGMPs and distributing incorrectly labeled drugs.

This announcement follows an FDA alert issued in April 2013 advising health care providers to remove drugs distributed by Shamrock Medical from supply stock due to the possibility that they were mislabeled. The warning covered many non-sterile medications and dosage forms, including tablets, vials, ophthalmic and otic solutions, and patches. Shamrock Medical’s representatives informed the court that they are no longer repackaging or distributing any drugs.

According to the consent decree approved by Judge Algenon L. Marbley of the Southern District of Ohio, if Shamrock Medical decides to resume operations, the company must first notify the FDA of their intention and will not be able to resume operations until they receive written notice from the FDA that their operations are compliant with the Federal Food, Drug, and Cosmetic Act and all applicable regulations.

In addition, the company is required to retain an independent expert to inspect their operations and have the expert certify to the FDA that the necessary corrections have been made, prior to resuming operations. FDA reports it has not received reports of harm to patients from use of these drug products; the agency does not anticipate a drug shortage as a result of today’s consent decree.

Source: FDA



blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here